Respiratory medicine
-
Respiratory medicine · Jan 2019
Randomized Controlled Trial Comparative StudyLung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.
In the INPULSIS® trials, nintedanib reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing of disease progression. We characterised the effects of nintedanib on physiologic outcomes using pooled data from the INPULSIS® trials. ⋯ A range of physiologic outcome measures in the INPULSIS® trials support the effect of nintedanib on reducing disease progression in patients with IPF.